Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | CRHBP | P24387 | 1/20 | 0.58 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | BCL9 | O00512 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11515737 | 0.92 | MAPT (0.51) | MAPTCRHBPCRHR2L3MBTL1LMNA | |
| SCHEMBL11513899 | 0.91 | MAPT (0.50) | MAPTCRHBPCRHR2L3MBTL1LMNA | |
| SCHEMBL830301 | 0.89 | LMNA (0.56) | MAPTCRHBPCRHR2L3MBTL1LMNA | |
| SCHEMBL11708706 | 0.87 | MAPT (0.56) | MAPTCRHBPCRHR2L3MBTL1LMNA | |
| SCHEMBL15516165 | 0.86 | MAPT (0.59) | MAPTCRHBPCRHR2L3MBTL1LMNA | |
| SCHEMBL831079 | 0.85 | LMNA (0.52) | MAPTCRHBPCRHR2L3MBTL1LMNA | |
| SCHEMBL16261809 | 0.85 | LMNA (0.52) | MAPTCRHBPCRHR2L3MBTL1LMNA | |
| SCHEMBL16261887 | 0.84 | HTR2A (0.59) | MAPTCRHBPCRHR2LMNAKMT2A | |
| SCHEMBL829972 | 0.84 | KMT2A (0.64) | MAPTL3MBTL1LMNAKMT2AMEN1 | |
| SCHEMBL30283493 | 0.84 | ALDH1A1 (0.61) | MAPTL3MBTL1LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102174024-B | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS INC | 2015-02-11 | — | — | CN | disclosed |
| US-8158621-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8148525-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120045454-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| EP-1471915-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| CN-102174024-A | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS INC | 2011-09-07 | — | — | CN | disclosed |
| US-20110144330-A1 | 2,4-Pyrimidinediamine Compounds and their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| CN-1625400-B | 2, 4-pyrimidinediamine compounds and uses thereof | RIGEL PHARMACEUTICALS INC | 2011-04-13 | — | — | CN | disclosed |
| US-7906644-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| EP-2281563-A1 | 2,4-Pyrimidinediamine compounds and their uses | Rigel Pharmaceuticals, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
| CN-1625400-A | 2, 4-pyrimidinediamine compounds and uses thereof | RIGEL PHARMACEUTICALS INC (US) | 2005-06-08 | — | — | CN | disclosed |
| EP-0107216-B1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND METHOD OF CONTROLLING UNWANTED PLANT GROWTH | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1986-10-01 | — | — | EP | disclosed |
| US-4452626-A | Herbicidal 4-(benzotriazol-1-yl)phenoxy)alkanoic acids, esters and salts | SHELL OIL COMPANY (US) | 1984-06-05 | — | — | US | disclosed |
| EP-0107216-A1 | Heterocyclic compounds, their preparation, compositions containing them and method of controlling unwanted plant growth | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1984-05-02 | — | — | EP | disclosed |
| US-4439226-A | Herbicidal 4-((benzimidazol-1-yl)phenoxy)alkanoic acids, esters and salts | SHELL OIL COMPANY (US) | 1984-03-27 | — | — | US | disclosed |
| US-4348534-A | Preparation of 2-aryloxy-2-haloproptonic acid compounds | BASF AKTIENGESELLSCHAFT (DE) | 1982-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045454-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | MAPT 4104/4885CRHBP 4065/4885CRHR2 1902/4885 |
| US-20110144330-A1 | 2,4-Pyrimidinediamine Compounds and their Uses | FCER2, FCGR1A, FCGR2A | MAPT 4104/4885CRHBP 4065/4885CRHR2 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.